Investigations of Sorafenib for HCC Patients Who Have Residue Disease After Resection With Curative Intent
Phase of Trial: Phase IV
Latest Information Update: 27 Sep 2017
Price : $35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms SECURE
- Sponsors Bayer
- 22 Sep 2017 Status changed from active, no longer recruiting to completed.
- 05 Sep 2017 Planned End Date changed from 22 Aug 2017 to 8 Sep 2017.
- 15 Aug 2017 Planned End Date changed from 31 Jul 2017 to 22 Aug 2017.